Differences in 28-day mortality of severe COVID-19 patients by D-dimer level among those given unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant.
-
Among those given no anticoagulant, mortality increased as D-dimer levels increased
-
Among treatment group, mortality stayed about the same
-
“When D-dimer exceeding 3.0 μg/mL (6-fold of upper limit of normal, six ULN), ap- proximate 20% reduction in mortality with heparin treat was found (32.8% vs 52.4%, P = .017).”
-
Odds ratios, confidence intervals can be found in table 4 in child node
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Differences in 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant based on SIC score
Differences in 28-day mortality of severe COVID-19 patients by D-dimer level among those given unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant.
Evaluation of other predictors of 28-day mortality pertaining to clotting factors and heparin treatment
SIC score interpretation for COVID-19
Methods for evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Patient characteristics in study evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Discussion for evaluating 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group